Lipocine’s (LPCN) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Lipocine (NASDAQ:LPCN) in a report released on Monday, MarketBeat reports. HC Wainwright also issued estimates for Lipocine’s Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.47) EPS and FY2026 earnings at ($1.91) EPS.

Several other brokerages have also issued reports on LPCN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lipocine in a research note on Friday, March 27th. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $15.00.

Lipocine Trading Up 6.5%

LPCN stock opened at $2.13 on Monday. The company’s 50 day moving average is $7.78 and its 200 day moving average is $5.74. The stock has a market cap of $15.55 million, a price-to-earnings ratio of -1.26 and a beta of 1.09. Lipocine has a 1-year low of $1.81 and a 1-year high of $12.37.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.26. The company had revenue of $1.15 million for the quarter, compared to analysts’ expectations of $0.12 million. Lipocine had a negative net margin of 487.00% and a negative return on equity of 59.30%.

Insider Activity at Lipocine

In related news, Director John W. Higuchi acquired 40,000 shares of the company’s stock in a transaction dated Tuesday, April 7th. The stock was purchased at an average price of $2.03 per share, with a total value of $81,200.00. Following the completion of the purchase, the director owned 203,797 shares in the company, valued at $413,707.91. This trade represents a 24.42% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mahesh V. Patel acquired 25,000 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were bought at an average cost of $2.03 per share, with a total value of $50,750.00. Following the purchase, the chief executive officer owned 160,679 shares of the company’s stock, valued at approximately $326,178.37. This trade represents a 18.43% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders acquired 213,000 shares of company stock valued at $434,600. 6.35% of the stock is owned by insiders.

Institutional Trading of Lipocine

A number of institutional investors have recently made changes to their positions in LPCN. Citadel Advisors LLC purchased a new stake in shares of Lipocine during the third quarter valued at approximately $41,000. Jane Street Group LLC purchased a new stake in shares of Lipocine during the fourth quarter valued at approximately $85,000. Renaissance Technologies LLC boosted its stake in shares of Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after purchasing an additional 1,300 shares during the period. Boothbay Fund Management LLC purchased a new stake in shares of Lipocine during the fourth quarter valued at approximately $441,000. Finally, Geode Capital Management LLC boosted its stake in shares of Lipocine by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after purchasing an additional 1,374 shares during the period. Hedge funds and other institutional investors own 9.11% of the company’s stock.

More Lipocine News

Here are the key news stories impacting Lipocine this week:

• Positive Sentiment: Director John W. Higuchi purchased 40,000 shares at ~$2.03 (SEC-filed), increasing his stake materially — a strong signal of insider confidence that likely supported the stock’s intraday strength. Director John Higuchi Buys $81,200 in Lipocine Stock
• Positive Sentiment: CEO Mahesh Patel bought 25,000 shares at about $2.03, raising his holding nearly 18% — another direct insider purchase that may attract momentum buyers in a low-float, small-cap stock. Mahesh Patel Purchases 25,000 Shares
• Neutral Sentiment: HC Wainwright raised FY2026 and quarterly EPS estimates (narrowing projected losses) but maintained a “Neutral” rating — supportive to fundamentals but not a bullish analyst upgrade. HC Wainwright Neutral Rating and Estimates Update
• Neutral Sentiment: Lipocine’s recent quarter beat revenue and posted a smaller-than-expected EPS loss, which underpins the revised sell-side models but the company remains cash-consuming and loss-making. MarketBeat LPCN financial summary
• Negative Sentiment: Press coverage showed HC Wainwright language that could be interpreted as more cautious/downgrade-focused — any negative wording from a healthcare specialist can trigger short-term selling in thinly traded names. MSN: HC Wainwright Downgrades Coverage
• Negative Sentiment: Shareholder litigation inquiry announced by Johnson Fistel introduces legal risk and potential expense — a downside catalyst that can weigh on sentiment and valuation. Johnson Fistel Investigation Announcement

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.